lol..... sudah Kenyang lagi nak balik makan lagi mehh......

So many ppl still dreaming skim cepat kaya.......

Sooner or later become skim lambat mampus.....

没有更低，只有更加低

talk talk privatisation until CEO resigned sampai tak boleh tahan.......

Banyak sohai & sozai still dreaming skim cepat kaya....

Soon like Perisai skim lambat mampus......

If stuck then guna spanner gorek lorrr......

Keyman188 saw some idiots go other counters forum keep on promoting this stock.......

Kesian....kesian.....

If you no holding power then can join Skim cepat kaya counters......

On & off can limit up....but also can turn to skim lambat mampus......

Was...suddenly got sohai & sozai promoting energy counter here, Keyman188 thought Gtronic already venture into energy biz...

Memang banyak idiots tak boleh tahan to hold energy counters so long didn't move then go anyway promoting....

So tomorrow can catch 2.16 & 2.11 !!!!!!

TOO SAD to heard that...

But Keyman188 never touch YTL group all stocks...

Kesian...kesian...for those always dreaming Skim Cepat Kaya...

So just keep it for your own sovereigns subject to not turn to PN17 & delisted in future......

Sooner or later turn to Skim lambat mampus......

Kesian...kesian......

KW Tan already given so much lessons for those newbies, always hunting for value investment...

Sorry to say that Keyman188 not assistant or kaki member of KW Tan, Keyman188 just using KW Tan message to give stubborn forumer here only.....


Kesian...kesian...

Don't be fooled lahhh....incurred heavy loss every year...

Total outstanding debt about RM 470.616 million...

Number of share about 317.050 million share...

Now debt more than market value...

Anytime cash call by huge right issue......

Then wait another 6 months lorrr.......

This year not Energy world......

Maybe next year got chance lahhh....

Strongly advise better don't touch Khazanahs' holding company, majority heading downside risk...

Just look at

MAS (cash crunch)

Airport

Cimb

Axiata

UEM Sunrise

Uem Edgenda

IHH

Well prepare for coming Q3 results announcement...

Performance far better than expected...

No matter up or down...Keyman188 always very happy...

Better go down 2.60 again lucky happy...

Some time trading shares not only 'straight line' pattern......

better swing up & down more happy......

Keyman188 saw got sohai & sozai talking cock...

Keyman188 already gain handsome profit 2 rounds...

Now still holding 3rd round......

Better sohai & sozai do more homework...do more study...do more research then talk....

Memang sohai & sozai cock......

hee...hee...hee...

Wah...unexpected Big Boss buy in 1,500,000 million share...

sure Q3 quarterly result much better than expected.....cheers....

Today very high chance to break below 0.500 / 0.495 for closing......

So RIP...

so many retail investors still hoping "Skim Cepat Kaya"...

Soon can see towards "Skim lambat mampus"......


Kesian...kesian...kesian...

sudah makan kenyang baru "newbie" asking why down......


kesian......kesian......

RIP to heard...

time to learn value investment.....

time to learn...

not too many sellers...

only "operator" selling only...

market always hope...

hope become killer...

Lol....

Trap & con retail investors again...

Kesian...kesian...

Masih degil for dreaming.......time to wake up lorrr....

Wahh....now I know KYY is Malaysia Mr.Warren Buffet...

So many company also "Buy Call"...

No wonder loss million dollar also no rasa lahhh....

Haa...Keyman already started to pick up slowly slowly since last Friday

NO NEED to wait tomorrow...

I keep it until the target price can reach...

Soon can see to break 5.00 soon...

Australia to receive first batch of AstraZeneca COVID-19 vaccine in Jan 2021 - PM to say

(Sunday, 06 Sep 2020 8:57 PM MYT)

SYDNEY (Reuters) - Australia will receive the first doses of an AstraZeneca and Oxford University COVID-19 vaccine in January 2021 if trials prove successful, after Canberra agreed a deal to purchase a second potential vaccine, Prime Minister Scott Morrison will say on Monday.

Australia said in August it had signed a preliminary agreement with AstraZeneca for enough doses for its population of nearly 26 million, which would be manufactured locally by pharmaceutical company CSL.

That deal appeared in some doubt when CSL said its priority was manufacturing an alternative potential vaccine developed with the University of Queensland (UQ).

Agreeing a deal to overcome the potential roadblock, Australia will now also buy 51 million doses of the UQ vaccine.

It will take possession of the first 3.8 million doses of the AstraZeneca vaccine in January and February 2021, and then receive a further 30 million doses, Morrison will say in extracts from an announcement sent to Reuters.

AstraZeneca’s candidate is seen as a frontrunner in a global race to deliver an effective coronavirus vaccine.

"Australians will be among the first in the world to receive a safe and effective vaccine, should it pass late stage testing," Morrison will say.

Under the deal with UQ and CSL, Australia will buy 51 million doses of that tie-up's vaccine. The UQ and CSL candidate is scheduled to begin phase two trials in late 2020 and if all trials are successful it could be rolled out to Australians in mid-2021.

Both deals will cost in total A$1.7 billion ($1.24 billion), Morrison will say. Should both vaccines prove successful, Australia has secured to right to donate or sell on without a mark-up.

Health officials are discussing who will receive the first doses if trials are successful, Morrison will say. Vulnerable people, and front-line health care workers likely to be first in line, a source familiar with the details told Reuters.

The supply agreements come as Australia grapples with a second wave of infections in its second most populous state, Victoria. Australia has recorded more than 26,000 infections and 753 deaths.


##https://www.thestar.com.my/news/world/2020/09/06/australia-to-receive-first-batch-of-astrazeneca-covid-19-vaccine-in-jan-2021---pm-to-say

Australia to receive first batch of AstraZeneca COVID-19 vaccine in Jan 2021 - PM to say

(Sunday, 06 Sep 2020 8:57 PM MYT)

SYDNEY (Reuters) - Australia will receive the first doses of an AstraZeneca and Oxford University COVID-19 vaccine in January 2021 if trials prove successful, after Canberra agreed a deal to purchase a second potential vaccine, Prime Minister Scott Morrison will say on Monday.

Australia said in August it had signed a preliminary agreement with AstraZeneca for enough doses for its population of nearly 26 million, which would be manufactured locally by pharmaceutical company CSL.

That deal appeared in some doubt when CSL said its priority was manufacturing an alternative potential vaccine developed with the University of Queensland (UQ).

Agreeing a deal to overcome the potential roadblock, Australia will now also buy 51 million doses of the UQ vaccine.

It will take possession of the first 3.8 million doses of the AstraZeneca vaccine in January and February 2021, and then receive a further 30 million doses, Morrison will say in extracts from an announcement sent to Reuters.

AstraZeneca’s candidate is seen as a frontrunner in a global race to deliver an effective coronavirus vaccine.

"Australians will be among the first in the world to receive a safe and effective vaccine, should it pass late stage testing," Morrison will say.

Under the deal with UQ and CSL, Australia will buy 51 million doses of that tie-up's vaccine. The UQ and CSL candidate is scheduled to begin phase two trials in late 2020 and if all trials are successful it could be rolled out to Australians in mid-2021.

Both deals will cost in total A$1.7 billion ($1.24 billion), Morrison will say. Should both vaccines prove successful, Australia has secured to right to donate or sell on without a mark-up.

Health officials are discussing who will receive the first doses if trials are successful, Morrison will say. Vulnerable people, and front-line health care workers likely to be first in line, a source familiar with the details told Reuters.

The supply agreements come as Australia grapples with a second wave of infections in its second most populous state, Victoria. Australia has recorded more than 26,000 infections and 753 deaths.


##https://www.thestar.com.my/news/world/2020/09/06/australia-to-receive-first-batch-of-astrazeneca-covid-19-vaccine-in-jan-2021---pm-to-say

90% of China's Sinovac employees, families took coronavirus vaccine: CEO

06 Sep 2020 05:02PM (Updated: 06 Sep 2020 05:10PM)

BEIJING: About 90 per cent of Sinovac Biotech employees and their families have taken an experimental coronavirus vaccine developed by the Chinese firm under the country’s emergency use program, its chief executive said on Sunday (Sep 6).

The extent of inoculations under the emergency program, which China launched in July but has released few details about, points to how actively it is using experimental vaccines in the hopes of protecting essential workers against a potential COVID-19 resurgence, even as trials are still underway.

The program is intended for specific groups, including medical staffers and those who work at food markets and in the transportation and service sectors.

Sinovac, whose CoronaVac is in Phase 3 clinical trials and has been included in the emergency scheme, offered the candidate vaccine to approximately 2,000 to 3,000 employees and their families on a voluntary basis, CEO Yin Weidong told Reuters.

“As a vaccine developer and manufacturer, a new outbreak could directly impact our vaccine production,” Yin said on the sidelines of an international trade fair in Beijing, explaining why his company was included in the emergency program.

Data gathered from the program could offer evidence of the vaccine’s safety, but such data, which is not part of the registered clinical trial protocols, will not be used as main materials that regulators review in judging whether to approve the vaccine for commercial use, Yin said.

He said those who chose to be inoculated, including his wife and parents, had been informed of the potential side effects prior to taking the shot, and that its vaccine completing only early and mid-stage trials.

Yin, who also took the shot, said doctors asked about their health conditions before the vaccination, and the occurrence rate of adverse reaction among those vaccinated has been “very low”.

Side effects after taking CoronaVac include fatigue, fever and pain, with mostly mild symptoms, according to results of a mid-stage trial sponsored by Sinovac, involving 600 participants and published last month ahead of peer review.

No vaccine has passed final, large-scale trials to prove it is effective and safe enough to protect people against the virus that has led to over 870,000 deaths globally.

##https://www.channelnewsasia.com/news/asia/covid-19-vaccine-sinovac-china-ceo-13086522

90% of China's Sinovac employees, families took coronavirus vaccine: CEO

06 Sep 2020 05:02PM (Updated: 06 Sep 2020 05:10PM)

BEIJING: About 90 per cent of Sinovac Biotech employees and their families have taken an experimental coronavirus vaccine developed by the Chinese firm under the country’s emergency use program, its chief executive said on Sunday (Sep 6).

The extent of inoculations under the emergency program, which China launched in July but has released few details about, points to how actively it is using experimental vaccines in the hopes of protecting essential workers against a potential COVID-19 resurgence, even as trials are still underway.

The program is intended for specific groups, including medical staffers and those who work at food markets and in the transportation and service sectors.

Sinovac, whose CoronaVac is in Phase 3 clinical trials and has been included in the emergency scheme, offered the candidate vaccine to approximately 2,000 to 3,000 employees and their families on a voluntary basis, CEO Yin Weidong told Reuters.

“As a vaccine developer and manufacturer, a new outbreak could directly impact our vaccine production,” Yin said on the sidelines of an international trade fair in Beijing, explaining why his company was included in the emergency program.

Data gathered from the program could offer evidence of the vaccine’s safety, but such data, which is not part of the registered clinical trial protocols, will not be used as main materials that regulators review in judging whether to approve the vaccine for commercial use, Yin said.

He said those who chose to be inoculated, including his wife and parents, had been informed of the potential side effects prior to taking the shot, and that its vaccine completing only early and mid-stage trials.

Yin, who also took the shot, said doctors asked about their health conditions before the vaccination, and the occurrence rate of adverse reaction among those vaccinated has been “very low”.

Side effects after taking CoronaVac include fatigue, fever and pain, with mostly mild symptoms, according to results of a mid-stage trial sponsored by Sinovac, involving 600 participants and published last month ahead of peer review.

No vaccine has passed final, large-scale trials to prove it is effective and safe enough to protect people against the virus that has led to over 870,000 deaths globally.

##https://www.channelnewsasia.com/news/asia/covid-19-vaccine-sinovac-china-ceo-13086522

Sinovac Biotech's COVID-19 vaccine enters phase 3 trial globally

(18:41, 05-Sep-2020)

The COVID-19 vaccine produced by China's Sinovac Biotech has entered phase 3 trial globally. Helen Yang from the company says the clinical trial will be completed by the end of the year and, after approval, the vaccine will be available in the market soon at an affordable price.

##https://news.cgtn.com/news/2020-09-05/Sinovac-Biotech-s-COVID-19-vaccine-enters-phase-3-trial-globally-TxA9NOdPvq/index.html

Sinovac Biotech's COVID-19 vaccine enters phase 3 trial globally

(18:41, 05-Sep-2020)

The COVID-19 vaccine produced by China's Sinovac Biotech has entered phase 3 trial globally. Helen Yang from the company says the clinical trial will be completed by the end of the year and, after approval, the vaccine will be available in the market soon at an affordable price.

##https://news.cgtn.com/news/2020-09-05/Sinovac-Biotech-s-COVID-19-vaccine-enters-phase-3-trial-globally-TxA9NOdPvq/index.html

US CDC tells states to prep for Covid-19 vaccine distribution by November

(September 03, 2020 06:49 am +08)

(Sept 3): The U.S. Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October or early November, documents published by the agency showed on Wednesday.

The timing of release of any vaccine has taken on political importance as U.S. President Donald Trump seeks re-election in November, after putting substantial federal resources into vaccine development.

"For the purpose of initial planning, CDC provided states with certain planning assumptions as they work on state specific plans for vaccine distribution, including possibly having limited quantities of vaccines in October and November," a CDC spokeswoman told Reuters.

The New York Times had earlier reported that the CDC had contacted officials in all 50 states and five large cities with the documents.

The country's top infectious disease expert Anthony Fauci earlier on Wednesday said on MSNBC that based on the patient enrollment rate in COVID-19 vaccine trials underway, there could be enough clinical data to know by November or December that one of the vaccines is safe and effective.

The documents put online by the New York Times showed that the CDC is preparing for one or two vaccines for COVID -19 to be available in limited doses as soon as late October.

The vaccines may be available free of cost first to high-risk groups including health care works, national security personnel, residents and staff at COVID-19 long-term care facilities, the agency said in the documents.

Drug developers including Moderna Inc, AstraZeneca Plc and Pfizer Inc are leading the race to develop a safe and effective vaccine for the respiratory illness.

The documents describe two vaccine candidates that must be stored at temperatures of -70 and -20 degrees centigrade. Those storage requirements match profiles of candidates from Pfizer and Moderna.


##https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov

US CDC tells states to prep for Covid-19 vaccine distribution by November

(September 03, 2020 06:49 am +08)

(Sept 3): The U.S. Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October or early November, documents published by the agency showed on Wednesday.

The timing of release of any vaccine has taken on political importance as U.S. President Donald Trump seeks re-election in November, after putting substantial federal resources into vaccine development.

"For the purpose of initial planning, CDC provided states with certain planning assumptions as they work on state specific plans for vaccine distribution, including possibly having limited quantities of vaccines in October and November," a CDC spokeswoman told Reuters.

The New York Times had earlier reported that the CDC had contacted officials in all 50 states and five large cities with the documents.

The country's top infectious disease expert Anthony Fauci earlier on Wednesday said on MSNBC that based on the patient enrollment rate in COVID-19 vaccine trials underway, there could be enough clinical data to know by November or December that one of the vaccines is safe and effective.

The documents put online by the New York Times showed that the CDC is preparing for one or two vaccines for COVID -19 to be available in limited doses as soon as late October.

The vaccines may be available free of cost first to high-risk groups including health care works, national security personnel, residents and staff at COVID-19 long-term care facilities, the agency said in the documents.

Drug developers including Moderna Inc, AstraZeneca Plc and Pfizer Inc are leading the race to develop a safe and effective vaccine for the respiratory illness.

The documents describe two vaccine candidates that must be stored at temperatures of -70 and -20 degrees centigrade. Those storage requirements match profiles of candidates from Pfizer and Moderna.


##https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov

IJM, sweet entry spot

(By NST Business - August 27, 2020 @ 11:03am)

KUALA LUMPUR: IJM Corp Bhd's current share price of RM1.27 (as at 10:23am Thursday) brings about a sweet entry spot to accumulate this sector heavyweight, RHB Research said.

This is despite IJM reporting first quarter (Q1) net profit of RM1.3 million, down 98 per cent quarter-on-quarter (QoQ), which is below RHB Research and consensus' estimates.

RHB said IJM's earnings were normalising and might point to stronger financial year 2022 numbers.

It said after falling 32 per cent in the last three months, the stock is now trading at an attractive 11 times financial year 2022 price earnings ratio versus a historical five-year mean of 16x.

"We remain upbeat that IJM's income visibility may be extended, on an expected healthy job pipeline next year.

"While the take-up rate for new units will likely remain soft compared to previous years, we believe the 1.1 roll-out of government relief measures will lend support in the near term.

"Note that unbilled sales stand at RM1.2 billion," it said.

Nevertheless, RHB Research has cut IJM's earnings forecast by 12 per cent, 12 per cent and 14 per cent respectively for financial years 2021-2023.

This is after adjusting for lower-than-expected earnings, mainly from the construction and property segments in the quarter.

"IJM's recent exclusion from the MSCI Global Index earlier this month may affect sentiment on the stock.

"However, we think this is only short-lived, as we expect more positive news flow relating to mega projects to surface from second half 2020 onwards," it said.

IJM has upgraded its "neutral" call on IJM to "buy" with a higher target price of RM1.69 from RM1.57 previously.


##https://www.nst.com.my/business/2020/08/619837/ijm-sweet-entry-spot

Big laughing...

when IB giving high target price then said be trusted...

When IB downgrade target price then said can not be trusted...

Market behaviour never never changed......

Another investment bank start to downgrade glove sector......

Foresee more & more IB will revise the downgrade target price soon...

Glove stocks slip as JF Apex Research downgrades sector

(theedgemarkets.com / August 27, 2020 11:54 am +08)

KUALA LUMPUR (Aug 27): Glove counters plunged this morning as the Covid-19 pandemic appears to let up and the faster-than-expected pace of vaccine development continues to pummel the sector.

Following a months-long rally which has ballooned glove makers' share prices, JF Apex Research has downgraded its rating on the sector to "neutral" from "overweight" amidst what it called a "reversal of fortune" that has dealt a blow to rubber gloves' demand.

The rating change comes after AmBank Research also downgraded its call on the sector to "neutral" considering that the share prices of glove makers were fully valued.

The research house reduced its target price for Hartalega Holdings Bhd to RM16.02 from RM21.62 and downgraded its call for the glove maker to "hold" from "buy".

Hartalega fell 1.55% or 26 sen to settle at RM16.50 at the time of writing with around 864,800 shares swapping hands so far.

The target price for Top Glove Corp Bhd is, however, maintained at RM25.40 as JF Apex believes it has higher spare capacity to cater to the huge demand of gloves globally as compared with Hartalega.

Top Glove was down 2.28% or 60 sen this morning to RM25.74, with around 3.66 million shares traded.

"Both target prices for Hartalega and Top Glove are in line with their five-year mean PE of 40x (54x which is at its +1SD previously) and unchanged PE of 30x respectively," the research house said in a note today.

Of the big four glove counters, Supermax Corp Bhd took the steepest dive, plummeting 4.14% or 88 sen to RM20.40, which makes it Bursa's top loser today.

Kossan Rubber Industries Bhd also fell 1.18% or 18 sen to RM15.12, just two days after reporting a record quarterly net profit of RM131.06 million.

JF Apex said the development of a Covid-19 vaccine is moving faster than expected as two vaccines are being approved for early or limited usage, expected to be distributed globally in the first or second quarter of next year. This would be negative news for glove makers, which have been riding on soaring glove demand brought about by the global pandemic.

The research house also said the spread of Covid-19 is decelerating, noting that countries worst hit by the virus such as the US and Brazil have seen a significant drop in their five-day moving average number of new cases from July's peak.

"Besides, around 57% of people across parts of India's financial hub of Mumbai have coronavirus antibodies from a study found in July which is very close to [the] 'herd immunity' [level of] 67%-70% of the population according to an expert from University of Chicago, despite Indian Covid-19 new cases growing at the fastest rate in the world," JF Apex added.

The momentum of rising average selling prices, which have contributed to bumper profits for glove companies recently, may not be as strong as initially thought as more companies venture into the sector while the rally is also seen to be taking a breather, according to the research house.

"We believe the PPE's (personal protective equipment) price rally has reached its end phase on the back of alleviating Covid-19 cases, faster-than-expected vaccine development, and supply catching up with demand amid prevailing strong awareness of personal or hygienic protection," JF Apex said.

Notably, the US has experienced a decline in hospitalised patients in tandem with its virus cases, which would spell a blow to demand and pricing for gloves as the country was the world's largest glove importer last year, willing to pay a premium for PPE due to the severity of its Covid-19 outbreak.

The research house added that less human interaction and social activities, which would slow the spread of the virus, have further reduced glove usage, citing Google mobility reports indicating that mobility trends across the US, Brazil and India have fallen drastically since the onset of the pandemic.


##https://www.theedgemarkets.com/article/glove-stocks-slip-jf-apex-research-downgrades-sector

As per 2019 annual report

Cash & Cash equivalent : RM 90,083,000

Less Loan & Borrowings : RM 28,831,000 + RM 9,915,000

So net cash now : RM 51,337,000


** Don't simply tembak

Big Boss is listening......

If limit up, sure my gangs will sell all to Big Boss....

Better slowly slowly moving better up & down......

AmBank Research says glovemakers fully valued, downgrades to 'neutral'

(theedgemarkets.com / August 25, 2020 16:01 pm +08)

KUALA LUMPUR (Aug 25): The run-up among glove counters may have peaked, said AmBank Research, which has downgraded its call on the sector to “neutral” from “overweight” in view that the share prices are fully valued.

In a research note this afternoon, AmBank Research opined that the elevated average selling prices (ASPs) enjoyed by glovemakers “will begin to taper off in 1Q21”.

The research house has Top Glove Corp Bhd, Kossan Rubber Industries Bhd and Hartalega Holdings Bhd under its coverage.

“Share prices of all of the glove companies under our coverage have exceeded their target prices,” it said.

“We believe that at current share price levels, the valuations for glove companies under our coverage have fully priced in the companies’ earnings outlook,” it said.

It added that “PE valuations are demanding” pointing out that Top Glove is currently trading at CY21F PE of 43.3 times, which is two standard deviations (SD) higher than its three-year average forward PE of 28.9 times, while Kossan Rubber’s CY21F PE of 26.0 times is almost 1SD higher than its three-year average forward PE of 23.7 times, and Hartalega is trading at a CY21F PE of 40.9 times, which is slightly higher than its three-year average PE of 39.5 times.

AmBank Research noted that the planned capacity increase of 126 billion pieces or 54% by end-2022 “will more than offset” demand increase, and that the recent strides in Covid-19 vaccines will affect ASPs as well.

AmBank downgraded Top Glove and Kossan to “hold” with unchanged fair values of RM25.70 and RM15.74 respectively, while maintaining a “hold” call on Hartalega with fair value of RM18.74. Currently, no glove stocks in Malaysia have any “sell” call by analysts covering the companies.



##https://www.theedgemarkets.com/article/ambank-research-says-glovemakers-fully-valued-downgrades-neutral

Seem like investment bank now re-evaluate the glove sector ready

Pfizer and BioNTech’s favored Covid-19 vaccine has fewer side effects than their first

(PUBLISHED THU, AUG 20 20208:17 PM EDT)

Pfizer and BioNTech surprised many industry watchers on July 27 when they announced they would conduct a large-scale study of a vaccine for Covid-19. The surprise? The vaccine that would be tested in a 30,000-patient trial wasn’t the one for which the companies had presented data on July 1.

The reason, the companies said, was that a second vaccine seemed to generate a similar immune response, but fewer side effects. On Thursday, they posted the results from all 332 people who received either vaccine, referred to as vaccines B1 or B2 — and indeed, B2 recipients experienced markedly fewer adverse events tied to the vaccine.

“Obviously, the better tolerated the vaccine, the more I think it will encourage public acceptance of a broad immunization,” said William Gruber, the senior vice president of vaccine clinical research and development at Pfizer. “Both would have been great candidates. We were fortunate that B2 actually satisfied having both a favorable immune profile and fewer reactions.”

The study tested doses of each vaccine ranging from 10 micrograms to 100 micrograms. The 30-microgram dose of B2 is being taken forward in clinical trials.

With the original vaccine, called BNT162b1, or B1 for short, patients between the ages of 18 and 55 had adverse events thought to be related to the vaccine 50% of the time at the 30-microgram dose. Those between the ages of 65 and 85 had related adverse events 16.7% of the time.

For the second vaccine, BNT162b2, or B2, patients between 18 and 55 had adverse events thought to be related to the vaccine 16.7% of the time, and no adverse effects thought to be related to the vaccine were reported in those between the ages of 65 and 85.

Both vaccines use mRNA — the genetic messenger the body uses to make the DNA code into proteins — packaged inside a fatty capsule, called a lipid nanoparticle, that allows it to get into cells. The mRNA instructs cells to make a protein, which then triggers the immune system into action. For the B1 vaccine, the mRNA coded for the part of a protein on the SARS-CoV-2 virus that binds to a receptor on human cells in order to gain entry to them. The B2 vaccine makes the entirety of this protein, known as the spike protein.

Using the full spike protein may allow the immune system to figure out more ways to detect and attack the virus. Chemical modifications to the mRNA may also explain some of the difference. Although the same dosage, by weight, was given to patients with each vaccine, the B2 vaccine would include fewer particles, because the full-length mRNA is heavier.

The side effects tracked were mostly those one would expect from a vaccine injection, including soreness at the injection site, fever, chills, headache, and muscle or joint pain. No older adult who received B2 reported redness or swelling at the injection site.

The average level of antibodies to the virus in older adults was only 41% that seen in younger participants. However, it was still higher than the level of antibodies seen in recovered patients, the authors said.

All patients in the study of B2 were white and non-Hispanic, with more older women than older men participating. The younger patients were a median of 37 years old, while the older ones were a median of 69.

Pfizer has said that some data from its large study of the B2 vaccine could come as early as October.


##https://www.cnbc.com/2020/08/20/pfizer-and-biontechs-favored-covid-19-vaccine-has-fewer-side-effects-than-their-first.html

Pfizer and BioNTech’s favored Covid-19 vaccine has fewer side effects than their first

(PUBLISHED THU, AUG 20 20208:17 PM EDT)

Pfizer and BioNTech surprised many industry watchers on July 27 when they announced they would conduct a large-scale study of a vaccine for Covid-19. The surprise? The vaccine that would be tested in a 30,000-patient trial wasn’t the one for which the companies had presented data on July 1.

The reason, the companies said, was that a second vaccine seemed to generate a similar immune response, but fewer side effects. On Thursday, they posted the results from all 332 people who received either vaccine, referred to as vaccines B1 or B2 — and indeed, B2 recipients experienced markedly fewer adverse events tied to the vaccine.

“Obviously, the better tolerated the vaccine, the more I think it will encourage public acceptance of a broad immunization,” said William Gruber, the senior vice president of vaccine clinical research and development at Pfizer. “Both would have been great candidates. We were fortunate that B2 actually satisfied having both a favorable immune profile and fewer reactions.”

The study tested doses of each vaccine ranging from 10 micrograms to 100 micrograms. The 30-microgram dose of B2 is being taken forward in clinical trials.

With the original vaccine, called BNT162b1, or B1 for short, patients between the ages of 18 and 55 had adverse events thought to be related to the vaccine 50% of the time at the 30-microgram dose. Those between the ages of 65 and 85 had related adverse events 16.7% of the time.

For the second vaccine, BNT162b2, or B2, patients between 18 and 55 had adverse events thought to be related to the vaccine 16.7% of the time, and no adverse effects thought to be related to the vaccine were reported in those between the ages of 65 and 85.

Both vaccines use mRNA — the genetic messenger the body uses to make the DNA code into proteins — packaged inside a fatty capsule, called a lipid nanoparticle, that allows it to get into cells. The mRNA instructs cells to make a protein, which then triggers the immune system into action. For the B1 vaccine, the mRNA coded for the part of a protein on the SARS-CoV-2 virus that binds to a receptor on human cells in order to gain entry to them. The B2 vaccine makes the entirety of this protein, known as the spike protein.

Using the full spike protein may allow the immune system to figure out more ways to detect and attack the virus. Chemical modifications to the mRNA may also explain some of the difference. Although the same dosage, by weight, was given to patients with each vaccine, the B2 vaccine would include fewer particles, because the full-length mRNA is heavier.

The side effects tracked were mostly those one would expect from a vaccine injection, including soreness at the injection site, fever, chills, headache, and muscle or joint pain. No older adult who received B2 reported redness or swelling at the injection site.

The average level of antibodies to the virus in older adults was only 41% that seen in younger participants. However, it was still higher than the level of antibodies seen in recovered patients, the authors said.

All patients in the study of B2 were white and non-Hispanic, with more older women than older men participating. The younger patients were a median of 37 years old, while the older ones were a median of 69.

Pfizer has said that some data from its large study of the B2 vaccine could come as early as October.


##https://www.cnbc.com/2020/08/20/pfizer-and-biontechs-favored-covid-19-vaccine-has-fewer-side-effects-than-their-first.html

Coronavirus live updates: Eviction protections are drying up; J&J plans 60,000 person vaccine trial

The U.S. reported over 47,400 new cases of the coronavirus on Wednesday, bringing the average number of new cases reported over the past seven days down to 47,487, according to a CNBC analysis of data compiled by Johns Hopkins University. That’s a drop in average new cases of over 11% compared with a week ago, marking a sustained decline in new cases across the country.


##https://www.cnbc.com/2020/08/20/coronavirus-updates-teachers-threaten-strikes-in-detroit-and-nyc-who-warns-of-resurgence-in-europe.html

Russia says coronavirus vaccine to be tested on 40,000 volunteers amid safety concerns

(PUBLISHED THU, AUG 20 20209:44 AM EDT)

~ The vaccine, called “Sputnik V,” has been hailed by Russian authorities as safe and effective after it received domestic regulatory approval earlier this month.

~ Full-scale production is due to start in September.

~ Health experts have expressed concern over the proposed vaccine, citing the speed of its approval and the lack of available data.


Russia claimed its coronavirus vaccine, the first to be registered worldwide, will soon be tested on 40,000 people in order to test its reliability.

The vaccine, called “Sputnik V,” has been hailed by Russian authorities as safe and effective after it received domestic regulatory approval earlier this month. Full-scale production is due to start in September.

Health experts and public officials, however, have expressed concern over the proposed vaccine, citing the speed of its approval and the lack of available data. The results of two months of small-scale human trials in Russia have not yet been made available to the public.

“The so-called conditioned registration certificate means that we are obliged to conduct an additional expanded clinical trial,” Denis Logunov, deputy director for scientific work of Gamaleya Research Institute of Epidemiology and Microbiology, said in an online briefing on Thursday, according to a translation.

“And currently we have agreed on a huge protocol for 40,000 participants. The purpose of this protocol is not that much to study the immunogenicity and safety of the vaccine, that goes without saying … But, additionally, we will have to assess the epidemic efficacy of this vaccine,” Logunov said.

Russia’s vaccine is being developed at the Gamaleya Research Institute in Moscow.

To date, more than 22.4 million people have contracted the Covid-19 infection, with 788,356 related deaths, according to data compiled by Johns Hopkins University.

WHO in talks with Russia over vaccine

Concerns over the safety and reliability of Sputnik V stem from the fact that it has only undergone rapid Phase 1 and Phase 2 clinical trials on a relatively small number of people.

Phase 3 trials are to begin shortly, but Russia has said it expects to start producing the vaccine as soon as next month.

When asked about Russia’s coronavirus vaccine during a separate online press briefing on Thursday, Hans Kluge, regional director for Europe at the WHO, replied: “Let me say, overall, that any advances in vaccine development is very encouraging news.”

The country has a “long tradition” of vaccine development and uptake, he added. “But … every vaccine has to go (through) the same rigorous standards of efficacy and safety. And, ultimately to know there is only one way to do so is clinical trials: Phase 1, Phase 2 and Phase 3 – including Phase 3,” Kluge said.

Catherine Smallwood, senior emergency officer at WHO Europe, also confirmed that the United Nations health agency had recently entered into direct discussions with Russia over the potential development of Sputnik V, with updates to follow in due course.

“This concern that we have around safety and efficacy is not specifically for the Russian vaccine, it is for all of the vaccines that are under development,” Smallwood said. “It is absolutely essential that we don’t cut corners in safety or efficacy, so it is a central concern for all of the vaccines.”

“We are not going through a rush job of trying to jump to conclusions here. We want to take our time to really understand where the vaccine is at and to get as full information as possible on the steps that have already been taken,” Smallwood said.


##https://www.cnbc.com/2020/08/20/russia-coronavirus-vaccine-to-be-tested-on-40000-volunteers-research-institute-claims.html

Okok...like that I parking 2.50...2.55...2.60...

Let seller match Keyman188 que order......

Sure limit down bohhhh.......

Don't let Keyman188 so happy until can't sleep lahhh...(kekeke...kekeke)

Aiya...Keyman188 tak greedy....

Tomorrow below RM 2.50, Keyman188 also want to wrack.......kekeke...kekeke...

Lol.......this fake new already came out this afternoon...

Got "Hackers" trying to attack Putin....

We know a lot of retailers now already stuck at glove counters since this whole week so depressed after big fall from high level...

Never mind, Keyman188 still hoping sell down more...Keyman188 want to collect more & more......

Aiya...don't worry lorrr...

Time always tell the market truth......

No need much arguements........

You better sell down more...Keyman188 collecting more......

What happen for Datuk Seri Stanley Thai case ???

I thought all already settled?? Why suddenly need court open file again !!!